Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5639863A · kind A · utility
10Cited by
0References
32Claims
0Family size
Inventor
Key dates
| Filing date | Jun 21, 1994 |
| Grant date | Jun 17, 1997 |
| Priority date | — |
| Expiry date | Jun 21, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The variable chains of two human monoclonal antibodies (HMAbs) of the IgM isotype are characterized by elucidation of cDNAs encoding those chains. The HMAbs are specific against cell cycle independent, glioma-associated antigen, and the antibodies do not recognize cultured normal human astrocytes. Immunoconjugates based on the sequences identified should target both proliferating and non-proliferating glioma cells in vivo, thus providing a valuable adjunctive therapy in the treatment of these tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.